Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

Fig. 3

Distribution of Ki67 by clinico-pathological factors Distribution of A Ki67Baseline for all patients, B Ki672weeks in patients allocated AI and C log-fold change Ki67 in patients allocated AI by clinico-pathological factors. Presented separately for HER2- and HER2 + patients

Back to article page